Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 4/2013

01.12.2013 | Myeloproliferative Disorders (JJ Kiladjian, Section Editor)

Molecular Classification of Myeloproliferative Neoplasms—Pros and Cons

verfasst von: Moosa Qureshi, Claire Harrison

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Dameshek first postulated a common myeloproliferative heritage for the myeloproliferative disorders, now termed neoplasms. This prescient observation was validated by the description of a common mutation in exon 14 of JAK2 for patients with essential thrombocythemia, polycythemia vera and primary myelofibrosis. In recent years, our knowledge of the molecular abnormalities underpinning these disorders has expanded significantly. At the same time, we have continued to use a classification based largely upon the first clinical descriptions of these entities, which sometimes proves problematic in differentiating between these conditions and normal reactive processes, myelodysplasia and between the myeloproliferative neoplasm entities themselves. Here, we discuss the pros and cons of a molecular classification and its potential utility in diagnosis, prognosis, and therapeutics.
Literatur
1.
Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008;22(1):3–13.PubMedCrossRef
2.
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.PubMed
3.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
4.
Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115(17):3842–7.PubMedCrossRef
5.
Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood. 2011;117(5):1472–82.PubMedCrossRef
6.
Laubach JP, Fu P, Jiang X, Salter KH, Potti A, Arcasoy MO. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol. 2009;37(12):1411–22.PubMedCrossRef
7.
Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120(6):2058–69.PubMedCrossRef
8.
Suzuki N, Yamazaki S, Ema H, Yamaguchi T, Nakauchi H, Takaki S. Homeostasis of hematopoietic stem cells regulated by the myeloproliferative disease associated-gene product Lnk/Sh2b3 via Bcl-xL. Exp Hematol. 2012;40(2):166–74.PubMedCrossRef
9.
Seeger T, Schanne D, Pahl H. Expression of the transcription factor NF-E2 is regulated via the novel epigenetic JAK2/H3Y41PH/HP1A pathway [abstract]. Haematol EHA Abstr Book. 2013;98(s1):106.
10.
Peeken J, Wehrle J, Gothwal M, Seeger T, Pahl H. Characterization of JMJD1C and JMJD2C as novel NF-E2 target genes [abstract]. Haematol EHA Abstr Book. 2013;98(s1):106.
11.
• Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209(2)):259–73. First descriptions of mechanisms of JAK 2 inhibitor resistance in vitro and mechanisms to potentially overcome them.PubMedCrossRef
12.
• Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489:155–9. First descriptions of mechanisms of JAK 2 inhibitor resistance in vitro and mechanisms to potentially overcome them.PubMedCrossRef
13.
Akada H, Akada S, Yan D, Hutchison R, Mohi G. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice [abstract]. ASH Annu Meet Abstra. 2012;120:809.
14.
Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931–40.PubMedCrossRef
15.
Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–307.PubMedCrossRef
16.
• Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 2012;120(13):2704–7. Insight into clonal expansion in MPN and its role in disease phenotype.PubMedCrossRef
17.
Saliba J, Hamidi S, Stefano AD, Langlois T, Lenglet G, Secardin L, et al. Modeling JAK2V617F heterozygous and homozygous mutations by using induced pluripotent stem cells derived from myeloproliferative neoplasms patients [abstract]. ASH Annu Meet Abstra. 2012;120:1758.
18.
Godfrey AL, Chen E, Pagano F, Silber Y, Campbell PJ, Green AR. Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica. 2013;98:718–21.PubMedCrossRef
19.
Huang L, Yao H, Ma Y. JAK2 signaling specifies phenotypic pleiotropy in myeloproliferative neoplasms [abstract]. ASH Annu Meet Abstra. 2012;120:2868.
20.
Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668–76.PubMedCrossRef
21.
Pérez C, Pascual M, Martin-Subero JI, Bellosillo B, Segura V, Delabesse E et al. Aberrant DNA methylation profile of chronic and transformed classic philadelphia-negative myeloproliferative neoplasms. Haematologica 2013 May 28 [Epub ahead of print].
22.
• Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013;73(3):1076–85. Data regarding methylation and modification of DNA in the different subtypes of MPN.PubMedCrossRef
23.
Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24.PubMedCrossRef
24.
• Zhan H, Cardozo C, Raza A. MicroRNAs in myeloproliferative neoplasms. BJH. 2013;161:471–83. A useful review of micro RNA and discussion of data regarding their potential role in MPN.PubMedCrossRef
25.
• Zhan H, Cardozo C, Yu W, Wang A, Moliterno AR, Dang CV, et al. MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis. 2012;50:190–5. A useful review of micro RNA and discussion of data regarding their potential role in MPN.PubMedCrossRef
26.
Hinds DA, Barnholt KE, Zehnder JL, Kiefer AK, Do CB, Eriksson N, et al. A germline variant in the TERT gene is a novel predisposition allele associated with myeloproliferative neoplasms [abstract]. ASH Annu Meet Abstra. 2012;120:707.
27.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.PubMedCrossRef
28.
Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V> F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840–6.PubMedCrossRef
29.
Barosi G, Poletto V, Massa M, Campanelli R, Villani L, Bonetti E, et al. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. PLoS One. 2013;8(3):e59791.PubMedCrossRef
30.
•• Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013 Apr 26 [Epub ahead of print]. Novel and strong data supporting the incorporation of molecular data into clinical risk profile and perhaps then into classification.
31.
•• Lasho TL, Gangat N, Finke C, Laborde RR, Hanson CA, Ketterling RP, et al. Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus [abstract]. ASH Annu Meet Abstra. 2012;120:430. Novel and strong data supporting the incorporation of molecular data into clinical risk profile and perhaps then into classification.
32.
Moliterno AR, Williams DM, McDevitt MA, Stein BL, Gerber JM, Rogers O, et al. Polycythemia Vera: redefinition in the genomic era [abstract]. ASH Annu Meet Abstra. 2012;120:1754.
33.
Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–17.PubMedCrossRef
34.
•• Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. JAK inhibitor trials in myelofibrosis.PubMedCrossRef
35.
•• Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–98. JAK inhibitor trials in myelofibrosis.PubMedCrossRef
36.
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–27.PubMedCrossRef
37.
Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789–96.PubMedCrossRef
38.
Talpaz M, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, et al. A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF. [abstract]. ASH Annu Meet Abstra. 2012;120:2837.
39.
Komrokji R, Wadleigh M, Seymour J, Roberts A, To L, Zhu H, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis [abstract]. ASH Annu Meet Abstra. 2011;118:282.
40.
Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;6:1322–7.CrossRef
41.
Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012;26(4):708–15.PubMedCrossRef
42.
Jamal R, Belisle C, Lessard MC, Hebert J, Roy DC, Levine R, et al. Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia. 2008;22:1472–4.PubMedCrossRef
43.
Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, et al. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. BJH. 2013;161:667–76.PubMedCrossRef
44.
Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550–60.PubMedCrossRef
45.
Choong ML, Pecquet C, Tai SJ, Yong JWY, Pendharkar V, Wang S, et al. Combination treatment with JAK2 and PI3K inhibitors in myeloproliferative neoplasms [abstract]. ASH Annu Meet Abstra. 2012;120:180.
46.
Vannucchi AM, Bartalucci N, Bogani C, Martinelli S, Tozzi L, Bosi A, et al. Combined inhibition of JAK2 and mTOR signaling results in enhanced efficacy in in-vitro and preclinical mouse models of JAK2V617F-driven myeloproliferative disease [abstract]. ASH Annu Meet Abstra. 2012;120:708.
47.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069–76.PubMedCrossRef
48.
Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One. 2013;8(1):e54826.PubMedCrossRef
49.
Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013;12(5):577–88.PubMedCrossRef
50.
Levine RL, Koppikar P, Marubayashi S, Bhagwat N, Taldone T, Park Y, et al. Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo [abstract]. ASH Annu Meet Abstra. 2012;120:805.
51.
Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114(24):5024–33.PubMedCrossRef
52.
Deangelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. BJH. 2013. doi:10.​1111/​bjh.​12384 [Epub ahead of print].PubMed
53.
Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). BJH. 2013;161(1):68–75.PubMedCrossRef
54.
Harrison C, Kiladjian JJ, Passamonti F, Vannucchi A, Acharyya S, Woo M, et al. A phase 1B, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (MF), post-polycythemia vera MF (PPV-MF), or post-essential thrombocythemia MF (PET-MF) [abstract]. Haematol EHA Abstr Book. 2012;97(s1):146.
55.
Akada H, Akada S, Gajra A, Bair A, Graziano S, Hutchison RE, et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012;119(16):3779–89.PubMedCrossRef
56.
Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. BJH. 2013. doi:10.​1111/​bjh.​12416 [Epub ahead of print].PubMed
57.
Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. BJH. 2013;161(5):688–94.PubMedCrossRef
58.
Gao SM, Chen CQ, Wang LY, Hong LL, Wu JB, Dong PH, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol. 2013;41(3):261–70.PubMedCrossRef
59.
Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma. 2013;54(2):242–51.PubMedCrossRef
60.
Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692–702.PubMedCrossRef
61.
Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418–24.PubMedCrossRef
62.
Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864–71.PubMedCrossRef
63.
Baerlocher GM, Leibundgut EO, Ayran C, Blaney M, Burington B, Morfeld D, et al. Imetelstat rapidly induces and maintains substantial hematologic and molecular responses in patients with Essential Thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results [abstract]. ASH Annu Meet Abstra. 2012;120:179.
64.
Nelson EA, Sharma SV, Settleman J, Frank DA. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget. 2011;2(6):518–24.PubMed
65.
Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421–9.PubMedCrossRef
Metadaten
Titel
Molecular Classification of Myeloproliferative Neoplasms—Pros and Cons
verfasst von
Moosa Qureshi
Claire Harrison
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2013
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-013-0179-9

Weitere Artikel der Ausgabe 4/2013

Current Hematologic Malignancy Reports 4/2013 Zur Ausgabe

Myeloproliferative Disorders (JJ Kiladjian, Section Editor)

The New Landscape of Therapy for Myelofibrosis

Multiple Myeloma (R Niesvizky, Section Editor)

Incorporating Novel Agents in the Management of Elderly Myeloma Patients

Multiple Myeloma (R Niesvizky, Section Editor)

New Approaches to Smoldering Myeloma

Myelodysplastic Syndromes (M Sekeres, Section Editor)

Standardizing the Initial Evaluation for Myelodysplastic Syndromes

Myeloproliferative Disorders (JJ Kiladjian, Section Editor)

Genetic Basis of MPN: Beyond JAK2-V617F

Myelodysplastic Syndromes (M Sekeres, Section Editor)

There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise